Matinas BioPharma is no longer a functioning drug developer. After pausing the oral amphotericin program and cutting research spend to nothing, the Bedminster holding company signed a pair of July agreements that convert the listed equity into a minority stub inside an Ontario clean-energy parent and sell the remaining lipid nanocrystal platform to a private specialty-drug buyer. That is a full identity change, not a partnership overlay. Legacy holders keep a thin claim on whatever the buyer can list, not on a Phase Three antifungal franchise.
The tension sits in the capital structure rather than in the science. Mid-year cash was only $761 thousand against an explicit going-concern warning, and book equity had already fallen to $1,800 thousand. Subsequent July paper raised a few million more, but the first-half operating drain still ran above $3 million. NYSE American has already flagged the equity shortfall and accepted a compliance plan that runs into late twenty twenty-seven. The market now prices the common near sixteen cents, a capitalization just above $2 million, which treats the clean-energy story as a low-probability option rather than a funded industrial plan.
The second-quarter print is useful only as evidence that the old business has already been wound down. Research and development was zero, overhead was the entire cost base, and the Bridgewater lab lease ended in a cash settlement. The question the next several months resolve is whether the GH Power combination and the Azurity sale both close before cash, listing status, or stockholder consent give out. If they do, holders own about nine percent of a pre-revenue reactor developer. If they do not, the board has already named winddown as the residual path.